Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...
Study represents the largest randomized Phase III trial comparing proton to traditional radiation with photons for ...
Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...
Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...
For patients with advanced oropharyngeal cancer, proton therapy may beat photon radiotherapy in terms of overall survival and ...
The initial closing of the transaction will coincide with Inversagen AI’s first financing round, anticipated by 30 January ...
Stocktwits on MSN
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial
The financing uses a single-asset SPV, allowing BioAtla to fund a pivotal study without a broader equity raise. ・BioAtla ...
BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction. BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for ...
USA: A large US-based phase III clinical trial has shown that proton radiotherapy offers a meaningful survival advantage and reduced toxicity compared with conventional photon radiotherapy for ...
The biggest stories of the day delivered to your inbox.
At five years, 90.9% of proton patients were alive compared to 81% with traditional radiation Proton therapy also showed benefits in quality of life, such as less feeding tube dependence, less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback